PBMs Will Stay in Crosshairs as Trump Antitrust Team Settles in

President-elect Donald Trump is expected to continue the Biden administration’s antitrust enforcement actions against pharmacy benefit managers and major insurers as rising health-care costs remain a bipartisan concern, antitrust experts say.

“I don’t see any sort of back down on enforcement when it comes to health-care under the Trump administration,” said Michelle A. Mantine, leader of the antitrust and competition team at Reed Smith LLP in Pittsburgh. “When you look across the landscape, we see scrutiny on all sorts of health-care related transactions, from pharma to hospital mergers to provider transactions.”

Health-care entities have increasingly become the target of antitrust ...